Deerfield Management Company, L.P. (Series C) Edgewise Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,078,509 shares of EWTX stock, worth $50.9 Million. This represents 1.37% of its overall portfolio holdings.
Number of Shares
2,078,509
Previous 1,781,006
16.7%
Holding current value
$50.9 Million
Previous $47.5 Million
16.75%
% of portfolio
1.37%
Previous 0.88%
Shares
4 transactions
Others Institutions Holding EWTX
# of Institutions
216Shares Held
98.4MCall Options Held
885KPut Options Held
232K-
Orbimed Advisors LLC San Diego, CA15MShares$368 Million10.86% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$218 Million3.85% of portfolio
-
Baker Bros. Advisors LP New York, NY6.16MShares$151 Million1.82% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$147 Million0.0% of portfolio
-
Novo Holdings Hellerup, G75MShares$123 Million10.85% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.55B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...